Home Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
 

Keywords :   


Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash

2014-12-08 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & LEXINGTON, Mass. Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days. Language: English Contact: MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: CBST Exchange: NASDAQ read more

Tags: share cash acquire pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »